Showing results (261-270 of 287) with videos related to
Sort By:
Pageof 29
The American Journal of Gastroenterology|January 9, 2013
Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial dataB Joseph Elmunzer, Peter D R Higgins, Sameer D Saini, et al.The American Journal of Gastroenterology|May 7, 2019
Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's DiseaseJing Wu, David M Lubman, Subra Kugathasan, et al.Alimentary Pharmacology & Therapeutics|November 27, 2023
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitisRemo Panaccione, Silvio Danese, Wen Zhou, et al.Gastroenterology|April 10, 2017
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a StudyBruce E Sands, Jingjing Chen, Brian G Feagan, et al.The American Journal of Gastroenterology|December 6, 2012
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion processLaurent Peyrin-Biroulet, Vincent Billioud, Geert D'Haens, et al.Cell|May 21, 2021
Charting human development using a multi-endodermal organ atlas and organoid modelsQianhui Yu, Umut Kilik, Emily M Holloway, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 28, 2021
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control StudyJeffrey A Berinstein, Jessica L Sheehan, Michael Dias, et al.Inflammatory Bowel Diseases|December 6, 2021
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVIDKimberly N Weaver, Xian Zhang, Xiangfeng Dai, et al.Gut|May 19, 2012
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trialWolfgang Hueber, Bruce E Sands, Steve Lewitzky, et al.Nature Medicine|February 19, 2020
Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiotaHiroko Nagao-Kitamoto, Jhansi L Leslie, Sho Kitamoto, et al.Pageof 29